India
Antimalarial Drugs Market is expected to grow steadily between 2024 and 2028,
with an impressive CAGR. This can be attributed to the high prevalence of
malaria, rising healthcare expenditure and increasing research &
development activities.
India has been a global
leader in the production of generic medicines, including antimalarial drugs,
for decades. With malaria being a major public health challenge in the country,
there has been a consistent demand for effective antimalarial drugs.
The presence of a high number
of pipeline items regarding antimalarial drugs in India is also positively
influencing the growth of the antimalarial drug market in the country. Plasmodium
falciparum, P. vivax, P. ovale, and P. malariae are the four types of malaria
parasites that affect people, according to the US-based Centre for Disease
Control and Prevention.
The Indian government has
implemented several initiatives to combat malaria, including the National
Vector Borne Disease Control Program. The program focuses on preventing and
controlling vector-borne diseases such as malaria, dengue, and chikungunya. The
government has also implemented policies to encourage the production of generic
drugs, which has helped to increase the availability and affordability of
antimalarial drugs in the country, thereby driving the growth of India
Antimalarial Drugs Market.
Indian pharmaceutical
companies are increasingly investing in research and development to develop new
and more effective antimalarial drugs. The government's support for innovation
in the healthcare sector is further driving R&D investment. This is
expected to result in the development of new drugs that are more effective
against drug-resistant strains of malaria, thereby creating lucrative
opportunities for the growth of India antimalarial drugs market in the next few
years.
There is a growing focus on
preventive healthcare in India, with people increasingly seeking to prevent
illnesses rather than just treating them. This has led to an increase in demand
for preventive measures, including antimalarial drugs. The trend towards
preventive healthcare is expected to support the growth of the India antimalarial
drugs market in the coming years.
India has strong partnerships
with several international organizations, including the World Health Organization
and the Global Fund to Fight AIDS, Tuberculosis and Malaria. These partnerships
have helped to increase access to antimalarial drugs in India and other
countries where malaria is endemic. Furthermore, these partnerships are
expected to drive further research and development, helping to develop more
effective drugs against drug-resistant strains of malaria, thereby fueling the
growth of India Antimalarial Drugs Market.
Several factors are impeding
the growth of India Antimalarial Drugs Market. These factors include poor
healthcare infrastructure, lack of awareness, competition from counterfeit
drugs, and pricing pressures. Drug resistance is a major problem in the
treatment of malaria, and it is a growing concern in India. There are several
drug-resistant strains of malaria, which makes it difficult to treat the
disease effectively. This has led to a significant decrease in the
effectiveness of some antimalarial drugs, and in turn, has led to a decrease in
demand for these drugs.
Rising Prevalence of Malaria
in India
The rising prevalence of
malaria in India is undoubtedly influencing the growth of antimalarial drugs in
the country. Malaria is a major public health problem in India, and its
prevalence has been increasing over the past few years. This has led to an increased
demand for effective and affordable antimalarial drugs in the country. According
to WHO, World Malaria Report 2022, India accounted for 79% of malaria cases in
the South East Asia region and about 83% of all malaria deaths in the WHO
South-East Asia Region. The Indian pharmaceutical industry has responded to
this demand by investing in research and development of new antimalarial drugs.
Several Indian pharmaceutical companies have developed and marketed various
antimalarial drugs that are affordable and accessible to the people in need.
These drugs have been developed using indigenous technology and expertise, and
they have helped in addressing the increasing demand for antimalarial drugs in
the country. Furthermore, the Indian government has also initiated various
programs and schemes to provide free or subsidized antimalarial drugs to the
people in need, particularly in the rural areas. These programs and schemes
have helped in improving the accessibility and affordability of antimalarial
drugs in the country.
Moreover, the regulatory
framework for drug development and approval in India is still evolving and can
be challenging for new drug development. The lack of clear regulatory
guidelines and processes can make it difficult for companies to obtain
approvals for new drugs, which can slow down the growth of the antimalarial
drug market in India.
Increasing R&D Activities
The increasing research and
development (R&D) activities regarding antimalarial drugs in India are
positively influencing the growth of the antimalarial drug market in the
country. The R&D activities have led to the development of new drug
molecules and formulations, which have shown promising results in clinical
trials. According to clinicaltrials.gov, there are around 32 studies related
to antimalarial drugs which are in different phases of development in India. This
in turn will bring a lot of new drugs into the market in the coming years. These
new drugs are expected to provide better treatment outcomes, reduce drug
resistance, and increase patient compliance.
Furthermore, the R&D
activities have also led to the development of novel drug delivery systems and
technologies, such as liposomal drug delivery systems and nano-formulations,
which can improve the efficacy and safety of antimalarial drugs. Moreover, the
Indian government has been supporting R&D activities in the field of
antimalarial drugs through various initiatives and schemes. The government has
established research institutions and laboratories, such as the National
Institute of Malaria Research (NIMR) and the Central Drug Research Institute
(CDRI), which are engaged in R&D activities to develop new antimalarial
drugs. All these factors are expected to support the growth of India
antimalarial drugs market in the forecast period.
Presence of High Number of
Pipeline Items
The presence of a high number
of pipeline items regarding antimalarial drugs in India is influencing the
growth of the antimalarial drug market in the country. The Indian
pharmaceutical industry has a robust pipeline of antimalarial drugs in various
stages of development, ranging from pre-clinical to clinical trials.
The high number of pipeline
items indicates the growing interest of the Indian pharmaceutical industry in
the development of new antimalarial drugs. It is also an indication of the
increasing investment in research and development activities in the field of
antimalarial drugs in India.
Moreover, the presence of a
high number of pipeline items indicates the potential for innovation in the
antimalarial drug market in India. The pipeline items include novel drug
molecules, drug delivery systems, and technologies that can improve the
efficacy and safety of antimalarial drugs.
Furthermore, the high number
of pipeline items is expected to increase competition in the antimalarial drug
market in India. The competition can lead to better quality drugs, lower
prices, and increased accessibility of antimalarial drugs to the people in
need.
Download Free Sample Report
Market
Segmentation
India
Antimalarial Drugs Market can be segmented by drug class, by mechanism of
action, by distribution channel and by region. Based on drug class, the India Antimalarial Drugs market can be divided into Aryl
aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, and Others.
Based on Mechanism of action, the India Antimalarial Drugs market is divided into Treatment for Malaria and
Prevention from Malaria. Based on distribution channel, the market is divided into Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy. In terms of regions, India Antimalarial
Drugs market can be categorized into North, South, East and West
Market Players
Cipla Ltd, Sun
Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Strides Pharma
Science Ltd, Ipca Laboratories Ltd, Aurobindo Pharma Ltd, Alkem Laboratories
Ltd, Novartis India Ltd, Lupin Limited, Cadila Healthcare Ltd is some of the
leading players operating in the India Antimalarial Drugs Market. Various
companies operating in the market are following different strategies to stay
competitive and have an edge over the other players operating in the India Antimalarial Drugs
Market. For instance, Novartis
and Medicines for Malaria Venture (MMV) have announced their decision to move
forward with a Phase 3 study for a novel combination of ganaplacide and
lumefantrine-SDF in adults and children with malaria. This combination is
designed to treat uncomplicated Plasmodium falciparum and Plasmodium vivax
malaria, which are the two most common types of malaria. The decision to
advance to Phase 3 comes after positive results from earlier trials, which
showed that the combination was well-tolerated and highly effective. This
collaboration between Novartis and MMV is an important step towards developing
new and effective treatments for malaria, a disease that continues to affect
millions of people worldwide.
Similarly, Lupin, a leading
pharmaceutical company, has announced that it has received approval from the US
Food and Drug Administration (FDA) for its generic version of
Hydroxychloroquine Sulfate Tablets USP, 200 mg. Hydroxychloroquine Sulfate is a
medication used to treat and prevent malaria, as well as autoimmune diseases
such as lupus and rheumatoid arthritis. The approval of Lupin's generic version
provides an affordable alternative to the brand-name drug, helping to improve
access to treatment for patients.
Ipca Laboratories, an Indian
pharmaceutical company, has been in the news recently as one of its drugs,
hydroxychloroquine, is among the three therapies being studied by the World
Health Organization (WHO) in the fight against malaria.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
coverage
|
Revenue
forecast, volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments
covered
|
By Drug Class
By Mechanism of Action
By Distribution Channel
By Region
|
|
Regional
scope
|
North
India; South India; West India; East India
|
|
Key
companies profiled
|
Cipla Ltd, Sun Pharmaceutical Industries Ltd, Glenmark
Pharmaceuticals Ltd, Strides Pharma Science Ltd, Ipca Laboratories Ltd,
Aurobindo Pharma Ltd, Alkem Laboratories Ltd, Novartis India Ltd, Lupin
Limited, Cadila Healthcare Ltd
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, India Antimalarial Drugs Market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:
- India Antimalarial Drugs Market,
By Drug Class:
o
Aryl aminoalcohol
compounds
o
Antifolate compounds
o
Artemisinin
compounds
o
Others
· India Antimalarial Drugs Market, By Mechanism of Action:
o
Treatment for
Malaria
o
Prevention from
Malaria
· India Antimalarial Drugs Market, By Distribution Channel:
o
Hospital
Pharmacy
o
Retail
Pharmacy
o
Online
Pharmacy
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in India Antimalarial Drugs Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
India Antimalarial Drugs Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]